Hemophilia B
ORPHA:98879DiseaseX-linked recessiveChildhood, Infancy, Neonatal
Фенотипы (HPO)14
Очень частый (80–99%)14
HP:0000790Hematuria
HP:0001058Poor wound healing
HP:0002170Intracranial hemorrhage
HP:0003010Prolonged bleeding time
HP:0003645Prolonged partial thromboplastin time
HP:0004406Spontaneous, recurrent epistaxis
HP:0004846Prolonged bleeding after surgery
HP:0005261Joint hemorrhage
HP:0006298Prolonged bleeding after dental extraction
HP:0011858Reduced factor IX activity
HP:0012233Intramuscular hematoma
HP:0012541Cephalohematoma
HP:0040232Delayed onset bleeding
HP:0400008Menometrorrhagia
Эпидемиология101
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | 3 | Europe | Value and class |
| Point prevalence | 1-9 / 100 000 | 1 | Albania | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.44 | Algeria | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.54 | Argentina | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.2 | Armenia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.665 | Austria | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.16 | Azerbaijan | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.015 | Bangladesh | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.84 | Belarus | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.32 | Belgium | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.155 | Belize | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.045 | Bolivia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.265 | Bosnia and Herzegovina | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.535 | Brazil | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.775 | Bulgaria | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.795 | Chile | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.405 | Colombia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.645 | Costa rica | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.625 | Croatia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.49 | Cuba | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.195 | Cyprus | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.045 | Czech Republic | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.56 | Denmark | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.165 | Dominican Republic | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.25 | Ecuador | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.955 | Egypt | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.31 | El Salvador | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.065 | Eritrea | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.24 | Estonia | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.235 | Finland | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.5 | Georgia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.885 | Germany | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.075 | Greece | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.075 | Guatemala | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.17 | Honduras | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.115 | Hungary | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.695 | Iceland | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.095 | India | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.01 | Indonesia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.98 | Iran, Islamic Republic of | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.545 | Iraq | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.06 | Italy | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.495 | Korea, Republic of | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.76 | Latvia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.57 | Lithuania | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.235 | Luxembourg | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.205 | North Macedonia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.5 | Malaysia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.77 | Malta | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.29 | Mexico | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.37 | Moldova, Republic of | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.15 | Mongolia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.2 | Morocco | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.065 | Nepal | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.035 | Netherlands | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.855 | New Zealand | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.005 | Nigeria | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.975 | Norway | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.24 | Pakistan | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.84 | Palestinian Territory, occupied | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.24 | Peru | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.1 | Philippines | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.85 | Poland | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.93 | Portugal | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.265 | Qatar | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.73 | Russian Federation | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.15 | Saudi Arabia | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.04 | Senegal | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.715 | Serbia | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.045 | Sierra leone | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.545 | Singapore | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.995 | Israel | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.32 | Jamaica | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.745 | Jordan | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.13 | Kenya | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.33 | Lebanon | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.33 | Nicaragua | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.585 | Panama | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.375 | Paraguay | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.76 | Romania | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.28 | Slovakia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.82 | Slovenia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.525 | South Africa | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.765 | Spain | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.065 | Sri Lanka | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.115 | Sudan | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.85 | Sweden | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.375 | Switzerland | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.085 | Thailand | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.02 | Togo | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.37 | Tunisia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.31 | Turkey | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.01 | Ukraine | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.08 | United Kingdom | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.36 | Uruguay | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.285 | Uzbekistan | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.18 | Venezuela | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.14 | Viet Nam | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.35 | Zimbabwe | Value and class |
| Prevalence at birth | 1-9 / 100 000 | 1.665 | Worldwide | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.44 | France | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)